Abstracts to include preclinical data on several drug-Fc conjugate (DFC) candidates including multispecific CD73/PD-1 DFC, CCR5 targeting DFC and CBO421 (CD73 targeting DFC) SAN DIEGO, March 06, 2024 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will be presenting three abstracts and one…
wpengineMarch 6, 2024